<DOC>
	<DOC>NCT00437164</DOC>
	<brief_summary>Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.</brief_summary>
	<brief_title>A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criteria: Have been diagnosed by a doctor with Type 2 Diabetes Mellitus at least 3 months before Screening Have a body mass index within range 25 to 40.0kg/m2 inclusive Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or postmenopausal per protocol definition) Exclusion criteria: Significant weight loss or gain in the 3 months before screening Have used insulin to treat hyperglycemia within 3 months before screening Have a history of fluid retention Have uncontrolled high blood pressure Have liver disease Take loop diuretics (water pills), certain blood thinners, and/or St. Johns Wort. Have or have had certain kinds of cancer</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>NaBr</keyword>
	<keyword>Sodium Bromide</keyword>
	<keyword>DEXA Deuterium</keyword>
	<keyword>Total Body Water</keyword>
	<keyword>Insulin</keyword>
	<keyword>D2O</keyword>
	<keyword>GW677954</keyword>
	<keyword>Randomized Withdrawal</keyword>
	<keyword>T2DM</keyword>
</DOC>